Literature DB >> 19168585

Leptin enhances cell migration in human chondrosarcoma cells through OBRl leptin receptor.

Shu-Ning Yang1, Hsien-Te Chen, Hsi-Kai Tsou, Chun-Yin Huang, Wei-Hung Yang, Chen-Ming Su, Yi-Chin Fong, Wen-Pei Tseng, Chih-Hsin Tang.   

Abstract

Leptin, an adipocyte-derived cytokine that is closely associated with obesity, has recently been shown to be involved in carcinogenesis and cancer progression. Integrins are the major adhesive molecules in mammalian cells and have been associated with metastasis of cancer cells. In this study, we found that leptin increased the migration and the expression of alphavbeta3 integrin in human chondrosarcoma cells. We also found that human chondrosarcoma tissues and chondrosarcoma cell lines had significant expression of the long form (OBRl) leptin receptor, which was higher than that in normal cartilage and human primary chondrocyte. Leptin-mediated migration and integrin upregulation were attenuated by OBRl receptor antisense oligonucleotide. Activations of insulin receptor substrate (IRS)-1, phosphatidylinositol 3-kinase (PI3K), Akt and nuclear factor-kappaB (NF-kappaB) pathways after leptin treatment were demonstrated, and leptin-induced expression of integrin and migration activity was inhibited by the specific inhibitor, small-interfering RNA and mutant of IRS-1, PI3K, Akt and NF-kappaB cascades. Taken together, our results indicated that leptin enhances the migration of chondrosarcoma cells by increasing alphavbeta3 integrin expression through the OBR1/IRS-1/PI3K/Akt/NF-kappaB signal transduction pathway.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19168585     DOI: 10.1093/carcin/bgp023

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  17 in total

Review 1.  Oncogenic role and therapeutic target of leptin signaling in breast cancer and cancer stem cells.

Authors:  Shanchun Guo; Mingli Liu; Guangdi Wang; Marta Torroella-Kouri; Ruben R Gonzalez-Perez
Journal:  Biochim Biophys Acta       Date:  2012-01-24

Review 2.  Roles of leptin in bone metabolism and bone diseases.

Authors:  Xu Xu Chen; Tianfu Yang
Journal:  J Bone Miner Metab       Date:  2015-03-18       Impact factor: 2.626

3.  Obesity and the risk of cholangiocarcinoma: a meta-analysis.

Authors:  Jun-Shan Li; Tian-Jie Han; Nie Jing; Lei Li; Xiao-Hua Zhang; Feng-Zhen Ma; Ji-Yong Liu
Journal:  Tumour Biol       Date:  2014-04-13

4.  Cyclooxygenase-2 enhances alpha2beta1 integrin expression and cell migration via EP1 dependent signaling pathway in human chondrosarcoma cells.

Authors:  Ju-Fang Liu; Yi-Chin Fong; Chih-Shiang Chang; Chun-Yin Huang; Hsien-Te Chen; Wei-Hung Yang; Chin-Jung Hsu; Long-Bin Jeng; Chih-Yi Chen; Chih-Hsin Tang
Journal:  Mol Cancer       Date:  2010-02-23       Impact factor: 27.401

5.  Obesity affects the chondrocyte responsiveness to leptin in patients with osteoarthritis.

Authors:  Stéphane Pallu; Pierre-Jean Francin; Cécile Guillaume; Pascale Gegout-Pottie; Patrick Netter; Didier Mainard; Bernard Terlain; Nathalie Presle
Journal:  Arthritis Res Ther       Date:  2010-06-09       Impact factor: 5.156

Review 6.  Molecular pathways: adiponectin and leptin signaling in cancer.

Authors:  Michael N Vansaun
Journal:  Clin Cancer Res       Date:  2013-01-25       Impact factor: 12.531

Review 7.  The potential role of leptin in tumor invasion and metastasis.

Authors:  Amitabha Ray; Margot P Cleary
Journal:  Cytokine Growth Factor Rev       Date:  2017-11-11       Impact factor: 7.638

8.  Leptin's Pro-Angiogenic Signature in Breast Cancer.

Authors:  Ruben Rene Gonzalez-Perez; Viola Lanier; Gale Newman
Journal:  Cancers (Basel)       Date:  2013-09-06       Impact factor: 6.639

9.  Leptin promotes glioblastoma.

Authors:  Johnathan E Lawrence; Nicholas J Cook; Richard A Rovin; Robert J Winn
Journal:  Neurol Res Int       Date:  2012-01-04

10.  Leptin and Adiponectin: new players in the field of tumor cell and leukocyte migration.

Authors:  Kerstin Lang; Janina Ratke
Journal:  Cell Commun Signal       Date:  2009-12-23       Impact factor: 5.712

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.